FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.
Saved in:
| Title: | FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer. |
|---|---|
| Authors: | Stein L; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Murugesan K; Foundation Medicine Inc, Cambridge, MA, USA., Reeser JW; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Risch Z; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Wing MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Paruchuri A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Samorodnitsky E; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Hoskins EL; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Dao T; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Smith A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Le D; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Babcook MA; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Chang YS; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Avenarius MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Imam M; Florida Cancer Specialists, Orlando, FL, USA., Freud AG; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Roychowdhury S; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2024 Sep 17; Vol. 8 (1), pp. 207. Date of Electronic Publication: 2024 Sep 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-024-00683-x |
